JP2017521371A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521371A5
JP2017521371A5 JP2016569722A JP2016569722A JP2017521371A5 JP 2017521371 A5 JP2017521371 A5 JP 2017521371A5 JP 2016569722 A JP2016569722 A JP 2016569722A JP 2016569722 A JP2016569722 A JP 2016569722A JP 2017521371 A5 JP2017521371 A5 JP 2017521371A5
Authority
JP
Japan
Prior art keywords
ndc
moiety
drug
spacer
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016569722A
Other languages
English (en)
Japanese (ja)
Other versions
JP6573633B2 (ja
JP2017521371A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/032565 external-priority patent/WO2015183882A1/en
Publication of JP2017521371A publication Critical patent/JP2017521371A/ja
Publication of JP2017521371A5 publication Critical patent/JP2017521371A5/ja
Application granted granted Critical
Publication of JP6573633B2 publication Critical patent/JP6573633B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016569722A 2014-05-29 2015-05-27 ナノ粒子薬物コンジュゲート Active JP6573633B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462004738P 2014-05-29 2014-05-29
US62/004,738 2014-05-29
US201462094923P 2014-12-19 2014-12-19
US62/094,923 2014-12-19
PCT/US2015/032565 WO2015183882A1 (en) 2014-05-29 2015-05-27 Nanoparticle drug conjugates

Publications (3)

Publication Number Publication Date
JP2017521371A JP2017521371A (ja) 2017-08-03
JP2017521371A5 true JP2017521371A5 (enExample) 2019-01-10
JP6573633B2 JP6573633B2 (ja) 2019-09-11

Family

ID=53284649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016569722A Active JP6573633B2 (ja) 2014-05-29 2015-05-27 ナノ粒子薬物コンジュゲート

Country Status (13)

Country Link
US (4) US10111963B2 (enExample)
EP (2) EP3148591B1 (enExample)
JP (1) JP6573633B2 (enExample)
KR (2) KR102231672B1 (enExample)
CN (2) CN113082225A (enExample)
AU (1) AU2015267200B2 (enExample)
BR (1) BR112016027624A8 (enExample)
CA (2) CA3201974C (enExample)
DK (1) DK3148591T3 (enExample)
ES (1) ES2788865T3 (enExample)
PL (1) PL3148591T3 (enExample)
RU (1) RU2016144055A (enExample)
WO (1) WO2015183882A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
US9625456B2 (en) 2009-07-02 2017-04-18 Sloan-Kettering Institute For Cancer Research Fluorescent silica-based nanoparticles
RU2015132626A (ru) 2013-03-15 2017-04-25 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч Мультимодальные наночастицы на основе диоксида кремния
CN113349707A (zh) 2013-12-31 2021-09-07 纪念斯隆-凯特琳癌症中心 用于荧光源实时多通道成像的系统、方法和设备
ES2788865T3 (es) 2014-05-29 2020-10-23 Memorial Sloan Kettering Cancer Center Conjugados farmacéuticos de nanopartículas
ES2794778T3 (es) 2014-12-15 2020-11-19 Memorial Sloan Kettering Cancer Center Péptidos cíclicos con selectividad mejorada de unión a los nervios, nanoparticulos unidas con dichos péptidos cíclicos y uso de los mismos para imágenes en vivo de tejidos nerviosos en tiempo real
BR112017024328A2 (pt) 2015-05-29 2018-07-24 Univ Cornell métodos de tratamento usando nanopartículas ultrapequenas para induzir morte celular de células cancerosas privadas de nutrientes via ferroptose
AU2017258415B2 (en) * 2016-04-29 2023-03-30 Cornell University Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
BR112019000143A2 (pt) 2016-07-07 2019-04-16 Memorial Sloan Kettering Cancer Center sistemas de imagem e métodos para radiogenomia de câncer conduzido por partícula, baseado no conhecimento e preditivo
AU2018271781A1 (en) 2017-05-25 2019-12-12 Cornell University Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereof
EP3642599B1 (en) 2017-06-23 2025-01-08 Memorial Sloan-Kettering Cancer Center Method of imaging in vivo tissues using nanoparticles comprising a reference dye and a sensor dye.
RU2679075C1 (ru) * 2017-11-09 2019-02-05 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Конъюгат люминесцентных наночастиц диоксида кремния с рекомбинантными однодоменными нано - моноантителами C7b ламы, способными специфически взаимодействовать с рекомбинантным белком HER2/neu - аналогом природного рецептора эпидермального фактора роста EGFR/ERBB клеток человека
WO2019113004A1 (en) 2017-12-04 2019-06-13 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis
CA3115355A1 (en) 2018-10-16 2020-04-23 Silicycle Inc. Tunable process for silica capsules/spheres preparation and their use
GB201904336D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
US20230381349A1 (en) * 2020-10-06 2023-11-30 Washington University Methods and compositions for imaging and treating cancer
ES2963150T3 (es) 2020-10-27 2024-03-25 Elucida Oncology Inc Procedimientos para funcionalizar nanopartículas
CN112168977A (zh) * 2020-10-27 2021-01-05 西南大学 转铁蛋白修饰的二氧化硅荷载白藜芦醇及制备方法和应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870791A (en) 1972-04-24 1975-03-11 Heskel M Haddad Solid state ophthalmic medication delivery method
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4136177A (en) 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4255415A (en) 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4688506A (en) 1985-09-03 1987-08-25 Breems Martinus Van Boat sail control system
US4788603A (en) 1985-10-19 1988-11-29 Fuji Photo Film Co., Ltd. Camera for sequentially photographing a subject using a reference optical system and a telescopic optical system
US4812409A (en) 1986-01-31 1989-03-14 Eastman Kodak Company Hydrolyzable fluorescent substrates and analytical determinations using same
US4713224A (en) 1986-03-31 1987-12-15 The Boc Group, Inc. One-step process for purifying an inert gas
US4810636A (en) 1986-12-09 1989-03-07 Miles Inc. Chromogenic acridinone enzyme substrates
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
GB2330907A (en) 1997-10-28 1999-05-05 Applied Imaging Int Ltd A karyotyper and methods for producing karyotypes
CA2318779C (en) 1998-01-22 2009-08-25 Luminex Corporation Microparticles with multiple fluorescent signals
US6254852B1 (en) 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
EP1482956A1 (en) 2002-02-01 2004-12-08 Vanderbilt University Targeted drug delivery methods
US8620410B2 (en) 2002-03-12 2013-12-31 Beth Israel Deaconess Medical Center Multi-channel medical imaging system
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
WO2004108902A2 (en) 2003-06-04 2004-12-16 Visen Medical, Inc. Biocompatible fluorescent silicon nanoparticles
US20060173362A1 (en) 2004-10-08 2006-08-03 The Cleveland Clinic Foundation And Vanderbilt University Methods of medical imaging using quantum dots
US7653427B2 (en) 2004-11-12 2010-01-26 Intra-Medical Imaging LLC Method and instrument for minimally invasive sentinel lymph node location and biopsy
JP2008533157A (ja) 2005-03-14 2008-08-21 マサチューセッツ・インスティテュート・オブ・テクノロジー 疾患および障害の診断および処置のためのナノセル
JP2009501237A (ja) 2005-03-14 2009-01-15 ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 生物活性fus1ペプチドおよびナノ粒子−ポリペプチド複合体
US8084001B2 (en) 2005-05-02 2011-12-27 Cornell Research Foundation, Inc. Photoluminescent silica-based sensors and methods of use
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
US20070031328A1 (en) 2005-06-24 2007-02-08 Kung Hank F Radiolabeled-pegylation of ligands for use as imaging agents
FR2888753B1 (fr) 2005-07-21 2008-04-04 Commissariat Energie Atomique Vecteur cible avec fonction d'imagerie activable
EP1973575B1 (en) * 2005-12-22 2019-07-24 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
WO2008044138A1 (en) 2006-10-12 2008-04-17 Syddansk Universitet Optical nanosensor for detection of reactive oxygen species
US8838213B2 (en) 2006-10-19 2014-09-16 The General Hospital Corporation Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample, and effecting such portion(s)
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
WO2008073856A2 (en) 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
US20080255460A1 (en) 2007-04-13 2008-10-16 Ethicon Endo-Surgery, Inc. Nanoparticle tissue based identification and illumination
EP1995327A1 (en) 2007-05-21 2008-11-26 Humboldt Universität zu Berlin Probe for detecting a particular nucleic acid sequence
US20110028662A1 (en) * 2007-08-31 2011-02-03 Hybrid Silica Technologies, Inc. Peg-coated core-shell silica nanoparticles and methods of manufacture and use
DE102007052517A1 (de) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT-Verfahren mit zwei Filtersystemen
WO2009064964A2 (en) 2007-11-15 2009-05-22 The University Of California Switchable nano-vehicle delivery systems, and methods for making and using them
EP4060327A1 (en) 2007-12-21 2022-09-21 President and Fellows of Harvard College Sub-diffraction limit image resolution in three dimensions
US8389679B2 (en) 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
US9625456B2 (en) * 2009-07-02 2017-04-18 Sloan-Kettering Institute For Cancer Research Fluorescent silica-based nanoparticles
IN2012DN05099A (enExample) * 2009-12-16 2015-10-09 Brigham & Womens Hospital
PT2528625E (pt) * 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
US10732115B2 (en) 2012-06-22 2020-08-04 Cornell University Mesoporous oxide nanoparticles and methods of making and using same
US9695133B2 (en) 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
RU2015132626A (ru) 2013-03-15 2017-04-25 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч Мультимодальные наночастицы на основе диоксида кремния
ES2788865T3 (es) 2014-05-29 2020-10-23 Memorial Sloan Kettering Cancer Center Conjugados farmacéuticos de nanopartículas
BR112017024328A2 (pt) 2015-05-29 2018-07-24 Univ Cornell métodos de tratamento usando nanopartículas ultrapequenas para induzir morte celular de células cancerosas privadas de nutrientes via ferroptose
EP3642599B1 (en) 2017-06-23 2025-01-08 Memorial Sloan-Kettering Cancer Center Method of imaging in vivo tissues using nanoparticles comprising a reference dye and a sensor dye.

Similar Documents

Publication Publication Date Title
Gyimesi et al. Transporter-mediated drug delivery
Hu et al. Advances in peptide functionalization on mesoporous silica nanoparticles for controlled drug release
Sapra et al. Designer peptide and protein dendrimers: a cross-sectional analysis
Wang et al. Peptide-mediated nanocarriers for targeted drug delivery: developments and strategies
Jadhav et al. Peptide–drug conjugates as next-generation therapeutics: exploring the potential and clinical progress
Chang et al. Smart linkers in polymer–drug conjugates for tumor-targeted delivery
CN103402545B (zh) 疏水性经修饰肽及其在肝特异性靶向中的用途
Cheng et al. Activable cell-penetrating peptide conjugated prodrug for tumor targeted drug delivery
KR102051038B1 (ko) 나노입자 약물 컨쥬게이트
Boehme et al. Drug delivery and release systems for targeted tumor therapy
ES2527634T3 (es) Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
US9216228B2 (en) Receptor and antigen targeted prodrug
Yun et al. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery
Zhang et al. Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment
ES2269397T3 (es) Sistemas de ligando terapeuticos y de diagnostico que comprenden propiedades de union a moleculas de transporte y medicamentos que los contienen.
AU2001275525B2 (en) Tripeptide prodrug compounds
ES2269160T3 (es) Procedimiento para la preparacion de una formulacion medicamentosa inyectable.
Egorova et al. Smart delivery systems responsive to cathepsin B activity for cancer treatment
JP2009500431A5 (enExample)
ES2602731T3 (es) Nueva composición y métodos para el tratamiento de enfermedades relacionadas con el sistema inmunitario
Guan et al. Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of αvβ6-positive cancers
CN106573031A (zh) 双末端聚乙二醇化整合素‑结合肽及其使用方法
CN103080125A (zh) 用于治疗性结合物的短且含d氨基酸的多肽及其使用
WO2019061561A1 (zh) 一种药物递送体系及其制备方法与应用
JP2012521201A5 (enExample)